Low long-term efficacy and tolerability of add-on rufinamide in patients with Dravet syndrome

被引：33
|
作者：
Mueller, A. [1 ,2 ]
Boor, R. [3 ,4 ]
Coppola, G. [5 ]
Striano, P. [6 ]
Dahlin, M. [7 ]
von Stuelpnagel, C. [1 ,2 ]
Lotte, J. [1 ,2 ]
Staudt, M. [1 ,2 ]
Kluger, G. [1 ,2 ]
机构：
[1] Epilepsy Ctr Children & Adolescents, Neuropediat Clin, Schon Klin Vogtareuth, Vogtareuth, Germany
[2] Epilepsy Ctr Children & Adolescents, Clin Neurorehabil, Schon Klin Vogtareuth, Vogtareuth, Germany
[3] Univ Hosp Schleswig Holstein, No German Epilepsy Ctr Raisdorf, Kiel, Germany
[4] Univ Hosp Schleswig Holstein, Dept Neuropediat, Kiel, Germany
[5] Univ Naples 2, Clin Child Neuropsychiat, Naples, Italy
[6] Univ Genoa, Muscular & Neurodegenerat Dis Unit, G Gaslini Inst, Genoa, Italy
[7] Karolinska Hosp, Astrid Lindgren Childrens Hosp, S-10401 Stockholm, Sweden
来源：
EPILEPSY & BEHAVIOR | 2011年 / 21卷 / 03期
关键词：
Rufinamide; Dravet syndrome; SCN1A mutation; Refractory seizures; SEVERE MYOCLONIC EPILEPSY; LENNOX-GASTAUT-SYNDROME; INFANCY; SEIZURES; TRIAL; ENCEPHALOPATHIES; ADULTS; SCN1A;
D O I：
10.1016/j.yebeh.2011.04.057
中图分类号：
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号：
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要：
In this retrospective European multicenter study we evaluated the efficacy and tolerability of rufinamide in patients with Dravet syndrome and refractory seizures. Twenty patients were included: in 16 patients a SCN1A mutation was detected. The responder rate after 6 months was 20%, and after 34 months, 5%. The retention rate was 45% after 6 months and 5% after 34 months. Rufinamide treatment was stopped because of aggravation of seizures (30%), no effect (45%), and side effects (10%). The efficacy and long-term retention rate were low in our patients with Dravet syndrome and refractory seizures, far lower than in patients with Lennox-Gastaut syndrome: one-third of our patients experienced seizure aggravation. Therefore, rufinamide does not seem to be a suitable option for long-term treatment in patients with Dravet syndrome. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码：282 / 284
页数：3
相关论文
共 50 条
  • [1] Long-Term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Dravet Syndrome in an open-label, Extension Trial
    Halford, Jonathan
    Scheffer, Ingrid
    Nabbout, Rima
    Sanchez-Carpintero, Rocio
    Malawsky, Yael Shiloh
    Wong, Matthew
    Checketts, Daniel
    VanLandingham, Kevan
    [J]. NEUROLOGY, 2019, 92 (15)
  • [2] Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial
    Scheffer, Ingrid E.
    Halford, Jonathan J.
    Miller, Ian
    Nabbout, Rima
    Sanchez-Carpintero, Rocio
    Shiloh-Malawsky, Yael
    Wong, Matthew
    Zolnowska, Marta
    Checketts, Daniel
    Dunayevich, Eduardo
    Devinsky, Orrin
    [J]. EPILEPSIA, 2021, 62 (10) : 2505 - 2517
  • [3] Long-term effectiveness of add-on stiripentol: an observational study in Dravet syndrome and non-Dravet developmental and epileptic encephalopathies
    Aledo-Serrano, Angel
    Gil-Nagel, Antonio
    Martinez-Vicente, Laura
    Jimenez-Huete, Adolfo
    Toledano, Rafael
    Garcia Morales, Irene
    [J]. EPILEPSIA, 2021, 62 : 167 - 167
  • [4] LONG-TERM EFFICACY AND TOLERABILITY DATA ON TOPIRAMATE AS ADD-ON THERAPY IN PATIENTS WITH TREATMENT-RESISTANT EPILEPSY
    Papacostas, S.
    Dietis, A.
    Flourentzou, A.
    Stylianidou, G.
    Koukkoullis, R.
    Kkolou, E.
    [J]. EPILEPSIA, 2009, 50 : 194 - 195
  • [5] Long-Term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Dravet Syndrome (DS) in an Open-Label Extension (OLE) Trial
    Shiloh-Malawsky, Y.
    Scheffer, I
    Halford, J.
    Nabbout, R.
    Sanchez-Carpintero, R.
    Wong, M.
    Checketts, D.
    VanLandingham, K.
    [J]. ANNALS OF NEUROLOGY, 2019, 86 : S71 - S72
  • [6] Long-term efficacy and safety of perampanel as an add-on therapy in patients with epilepsy
    Arai, Yukika
    Inaji, Motoki
    Shimizu, Kazuhide
    Kondo, Shizukoto
    Hashimoto-Fujimoto, Satoka
    Kiyokawa, Juri
    Kawano, Yoshihisa
    Yamamoto, Shinji
    Maehara, Taketoshi
    [J]. EPILEPSY RESEARCH, 2024, 200
  • [7] Long-Term Safety And Efficacy Of Add-On Cannabidiol (CBD) Treatment In Patients With Dravet Syndrome In An Open-Label Extension Trial (GWPCARE5)
    Nabbout, R.
    Halford, J.
    Scheffer, I. E.
    Sanchez-Carpintero, R.
    Malawsky, Y. Shiloh
    Wong, M.
    Checketts, D.
    VanLandingham, K.
    [J]. EPILEPSIA, 2019, 60 : 63 - 63
  • [8] LONG-TERM EFFICACY AND TOLERABILITY OF TOPIRAMATE AS ADD-ON THERAPY IN REFRACTORY PARTIAL EPILEPSY: AN OBSERVATIONAL STUDY
    Lee, B.
    Cho, Y.
    Jang, S.
    Heo, K.
    [J]. EPILEPSIA, 2009, 50 : 193 - 193
  • [9] Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: An observational study
    Cho, Yang-Je
    Heo, Kyoung
    Kim, Won-Joo
    Jang, Sang Hyun
    Jung, Yo Han
    Ye, Byoung Seok
    Song, Dong Beom
    Lee, Byung In
    [J]. EPILEPSIA, 2009, 50 (08) : 1910 - 1919
  • [10] RUFINAMIDE AS ADD-ON TREATMENT FOR PATIENTS WITH LENNOX-GASTAUT SYNDROME
    Nakken, O.
    Eriksson, A.
    Lossius, M.
    Nakken, K.
    [J]. EPILEPSIA, 2009, 50 : 153 - 154
12345